Allied Biotech Corporation (TPEX:1780)
Taiwan
· Delayed Price · Currency is TWD 30.80
-0.25 (-0.81%)
Apr 29, 2026, 1:07 PM CST
Allied Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 849.51 | 806.92 | 720.43 | 716.75 | 676.76 | Upgrade
|
| Revenue Growth (YoY) | 5.28% | 12.01% | 0.51% | 5.91% | 9.50% | Upgrade
|
| Cost of Revenue | 540.9 | 548.53 | 473.99 | 445.7 | 418.71 | Upgrade
|
| Gross Profit | 308.61 | 258.38 | 246.44 | 271.05 | 258.05 | Upgrade
|
| Selling, General & Admin | 159.79 | 144.15 | 131.64 | 144.71 | 120.64 | Upgrade
|
| Research & Development | 28.43 | 26.12 | 26.09 | 24.56 | 25.74 | Upgrade
|
| Operating Expenses | 188.27 | 170.27 | 157.73 | 171.27 | 146.38 | Upgrade
|
| Operating Income | 120.34 | 88.12 | 88.71 | 99.78 | 111.67 | Upgrade
|
| Interest Expense | -17.32 | -13.96 | -12.96 | -11.75 | -11.25 | Upgrade
|
| Interest & Investment Income | 22.5 | 24.67 | 15.63 | 5.3 | 1.65 | Upgrade
|
| Currency Exchange Gain (Loss) | 36.22 | 30.92 | 29.88 | 88.11 | -85.55 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.24 | 0.29 | 1.12 | 5.01 | 1.06 | Upgrade
|
| EBT Excluding Unusual Items | 164.98 | 130.04 | 122.38 | 186.45 | 17.58 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.86 | - | - | -1.59 | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.17 | - | Upgrade
|
| Pretax Income | 164.12 | 130.04 | 122.38 | 185.04 | 17.58 | Upgrade
|
| Income Tax Expense | 34.67 | 29.1 | 24.97 | 38.29 | 4.54 | Upgrade
|
| Net Income | 129.46 | 100.94 | 97.41 | 146.74 | 13.04 | Upgrade
|
| Net Income to Common | 129.46 | 100.94 | 97.41 | 146.74 | 13.04 | Upgrade
|
| Net Income Growth | 28.25% | 3.62% | -33.62% | 1025.14% | -83.59% | Upgrade
|
| Shares Outstanding (Basic) | 96 | 96 | 96 | 95 | 95 | Upgrade
|
| Shares Outstanding (Diluted) | 96 | 96 | 96 | 96 | 95 | Upgrade
|
| Shares Change (YoY) | 0.10% | 0.37% | 0.20% | 0.43% | 0.05% | Upgrade
|
| EPS (Basic) | 1.35 | 1.05 | 1.02 | 1.54 | 0.14 | Upgrade
|
| EPS (Diluted) | 1.34 | 1.05 | 1.01 | 1.53 | 0.14 | Upgrade
|
| EPS Growth | 27.62% | 3.96% | -33.99% | 1018.40% | -83.52% | Upgrade
|
| Free Cash Flow | 127.62 | 196.98 | 89.71 | 109.62 | 22.44 | Upgrade
|
| Free Cash Flow Per Share | 1.32 | 2.04 | 0.94 | 1.14 | 0.23 | Upgrade
|
| Dividend Per Share | 1.250 | 1.000 | 0.850 | 1.200 | 0.500 | Upgrade
|
| Dividend Growth | 25.00% | 17.65% | -29.17% | 140.00% | -37.50% | Upgrade
|
| Gross Margin | 36.33% | 32.02% | 34.21% | 37.82% | 38.13% | Upgrade
|
| Operating Margin | 14.16% | 10.92% | 12.31% | 13.92% | 16.50% | Upgrade
|
| Profit Margin | 15.24% | 12.51% | 13.52% | 20.47% | 1.93% | Upgrade
|
| Free Cash Flow Margin | 15.02% | 24.41% | 12.45% | 15.29% | 3.32% | Upgrade
|
| EBITDA | 175.73 | 144.33 | 152.38 | 165.12 | 170.53 | Upgrade
|
| EBITDA Margin | 20.69% | 17.89% | 21.15% | 23.04% | 25.20% | Upgrade
|
| D&A For EBITDA | 55.39 | 56.21 | 63.67 | 65.34 | 58.86 | Upgrade
|
| EBIT | 120.34 | 88.12 | 88.71 | 99.78 | 111.67 | Upgrade
|
| EBIT Margin | 14.16% | 10.92% | 12.31% | 13.92% | 16.50% | Upgrade
|
| Effective Tax Rate | 21.12% | 22.38% | 20.41% | 20.70% | 25.81% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.